STRENGTHENING HEALTH CARE AND LOWERING PRESCRIPTION DRUG COSTS ACT
Amendments
Enact (H.R. 987), H3873, H3874, H3876, H3877, H3878, H3879, H3880, H3882, H3883, H3884, H3885, H3886, H3887, H3888, H3889, H3891, H3892, H3893, H3894, H3896, H3897, H3898, H3900, H3901 [16MY]
——— consideration (H. Res. 377), H3811 [15MY]
Bills and resolutions
Enact (H.R. 987): consideration (see H. Res. 377), H3787 [14MY]
Letters
Patient Protection and Affordable Care Act navigator program funding to assist in choosing plans and increase outreach about plan options and financial support availability: several medical organizations, H3875 [16MY]
Rule on definition of short-term limited duration insurance for purposes of its exclusion from the definition of individual health insurance coverage shall have no force or effect: several medical organizations, H3874 [16MY]
Motions
Enact (H.R. 987), H3904 [16MY]
Notices
Estimated budget effects of H.R. 987, provisions, H3786 [14MY], H3921 [16MY]
Remarks in House
Dept. of HHS: allow State-run health insurance marketplaces to be eligible for federally-facilitated marketplace navigator program funds, H3880, H3881 [16MY]
——— allow use of ‘‘silver loading’’ to make up for loss of cost-sharing reduction (CSR) payments to health insurance companies, H3867, H3868, H3879, H3880 [16MY]
——— establish annual enrollment targets for health insurance exchanges, H3896 [16MY]
——— extend deadline by which States may apply for Federal assistance to establish State-based marketplaces and extend date for State exchanges to be self-sustaining, H3887 [16MY]
——— prohibit termination of health insurance coverage for enrollees not actively enrolled during the most recent enrollment period, H3876 [16MY]
——— report on extent to which increases in prices of commonly prescribed drugs has caused individuals with health insurance to forego needed treatment, H3885, H3886 [16MY]
——— report on Patient Protection and Affordable Care Act marketing and outreach programs, H3877 [16MY]
——— report on use of Patient Protection and Affordable Care Act user fees to fund outreach and enrollment, navigator program, and maintenance of Healthcare.gov and its call centers, H3897 [16MY]
——— require navigators to provide information in plain language regarding essential health benefits and coverage and treatment parity for mental health and substance abuse, H3890, H3891 [16MY]
——— require navigators to receive training on how to assist consumers with Medicaid and State Children’s Health Insurance Program enrollment, H3886, H3887 [16MY]
——— require reports during annual open enrollment period on performance of the Federal exchange and the Small Business Health Options Program exchange, H3883 [16MY]
Depts. of HHS and Education: ensure access by students and faculty of pharmacy schools to information on use and availability of generic drugs and biosimilar biological products, H3882 [16MY]
Enact (H.R. 987), H3715 [10MY], H3731 [14MY], H3800 [15MY], H3851, H3852, H3853–H3911, H3913 [16MY], H4123 [23MY], H4401 [11JN], H5085 [25JN], H5175 [26JN], H7693 [12SE], H9248 [4DE], E623 [17MY]
——— consideration (H. Res. 377), H3801–H3813 [15MY]
——— corrections in engrossment, H3911 [16MY]
——— motion to recommit, H3908, H3909 [16MY]
FDA: increase competition in generic drug market by removing barriers for a second generic drug to come to market created by exclusivity period granted to a first generic drug application, H3800 [15MY], H3857, H3860 [16MY]
——— prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market, H3858, H3864, H3865, H3873 [16MY]
GAO: conduct cost benefit analysis of establishment of State-administered health insurance plans for States that may want to offer a public option in their health insurance exchanges, H3888 [16MY]
——— report on whether Dept. of HHS has taken appropriate steps to ensure that routine maintenance to Healthcare.gov website is minimally disruptive to consumers, H3889 [16MY]
——— study effect of cuts to Patient Protection and Affordable Care Act outreach and the Navigator Program on health insurance enrollment and costs of coverage, H3884, H3885 [16MY]
House of Representatives: accomplishments of 116th Congress, H4437 [12JN]
Insurance: provide that rule on definition of short-term limited duration insurance for purposes of its exclusion from the definition of individual health insurance coverage shall have no force or effect, H3859, H3863–H3865, H3867 [16MY]
——— recognize that short-term, limited duration insurance weakens protections for individuals living with preexisting health conditions, H3895 [16MY]
——— require a health insurance issuer offering short-term insurance to disclose certain information on coverage exclusions and premium variations and prohibit sale of such insurance during certain periods, H3895, H3896, H3898 [16MY]
National Academy of Medicine: study role of Federal funding and research in drug development, H3878 [16MY]
Patient Protection and Affordable Care Act: clarify ability of navigators to provide referrals to community-based organizations that address social needs related to health outcomes, H3892, H3893 [16MY]
——— ensure rural areas are included in navigator outreach, H3900, H3901 [16MY]
——— ensure veterans are included in navigator outreach, H3901, H3902 [16MY]
——— guarantee funding for navigator programs to provide assistance in choosing health plans and increase outreach and education about plan options and financial support availability, H3859 [16MY]
——— implement outreach and educational activities in areas with high health disparities, H3891, H3892 [16MY]
——— preserve State option to implement health care marketplaces, H3862 [16MY]
——— prioritize areas with high concentrations of unemployment for navigator program outreach and educational activities, H3898–H3900 [16MY]
——— provide opioid specific education and training for navigators and certified application counselors, H3879 [16MY]
——— require navigators to assist vulnerable populations including individuals with limited English proficiency and chronic illnesses, H3893, H3894 [16MY]
Pharmaceuticals: prohibit biological product manufacturers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market, H3800 [15MY], H3856 [16MY]
——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, H3800 [15MY], H3856 [16MY]
Remarks in Senate
Enact (H.R. 987), S6934 [10DE]
Reports filed
Consideration of H.R. 987, Provisions: Committee on Rules (House) (H. Res. 377) (H. Rept. 116–61), H3787 [14MY]
Tables
Estimated pay-as-you-go effects of H.R. 987, provisions, H3786 [14MY], H3921 [16MY]
Texts of
H. Res. 377, consideration of H.R. 987, provisions, H3801 [15MY]